Brigitte C. Widemann

Hematology | Oncology

8906 Bradmoor Dr
Bethesda, MD 20817

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 227 publications

Sustainable Community-Wide Model to Enhance Cancer Data Usage and Utility.

Sustainable Community-Wide Model to Enhance Cancer Data Usage and Utility.

Journal: JCO clinical cancer informatics

Published: August 14, 2026

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal: Journal for immunotherapy of cancer

Published: June 19, 2026

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal: Journal for immunotherapy of cancer

Published: June 19, 2026

New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis.

New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis.

Journal: Cancers

Published: June 02, 2026

A Framework for Prioritizing Novel Agents in Malignant Peripheral Nerve Sheath Tumor Trials: A report from the Neurofibromatosis Clinical Trials Consortium.

A Framework for Prioritizing Novel Agents in Malignant Peripheral Nerve Sheath Tumor Trials: A report from the Neurofibromatosis Clinical Trials Consortium.

Journal: Neuro-oncology

Published: May 13, 2026

Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors.

Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors.

Journal: Anticancer research

Published: April 29, 2026

Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

Journal: Neuro-oncology advances

Published: April 28, 2026

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Journal: Neuro-oncology advances

Published: April 27, 2026

Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated Analysis.

Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated Analysis.

Journal: JCO clinical cancer informatics

Published: April 08, 2026

Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.

Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.

Journal: Pediatric blood & cancer

Published: April 02, 2026

Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 10, 2026

Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative Tools.

Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative Tools.

Journal: JCO clinical cancer informatics

Published: December 10, 2025

Showing 1-12 of 227

Last Updated: 09/26/2026